Oncogene addiction is a phenomenon that the survival of cancer cells depends on 
an activated oncogene or inactivation of tumor suppressor gene, and is regarded 
as the 'Achilles heel' of the successful molecular targeted therapies in cancer. 
However, the role of oncogene addiction in gliomas has not been elucidated 
systematically. In this review, we summarize the current experimental and 
clinical evidence for the concept of oncogene addiction and describe the 
mechanisms explaining oncogene addiction in gliomas. And the clinical 
implications for oncogene addiction in molecular targeted therapy are further 
emphasized. In addition, we discuss future direction for defining complex 
"oncogene addiction network" through the integrated analysis of multiple 
platforms in the flow of genetic information in gliomagenesis.